The Patient Perspective: A Matter of Minutes

被引：6

作者：

Falchetto, Rocco ^{[1
]}

机构：

[1] Int Porphyria Patient Network, Hegarstr 3, CH-8032 Zurich, Switzerland

来源：

PATIENT-PATIENT CENTERED OUTCOMES RESEARCH | 2020年 / 13卷 / 01期

关键词：

ERYTHROPOIETIC PROTOPORPHYRIA; AFAMELANOTIDE;

D O I：

10.1007/s40271-019-00399-2

中图分类号：

R19 [保健组织与事业（卫生事业管理）];

学科分类号：

摘要：

引用

页码：1 / 6

页数：6

共 36 条

[1]

BARMANAKSOZEN J, 2019, PATIENT EMPOWERMENT, V3

[2] Long-term observational study of afamelanotide in 115 patients with erythropoietic protoporphyria [J].

Biolcati, G. ;

Marchesini, E. ;

Sorge, F. ;

Barbieri, L. ;

Schneider-Yin, X. ;

Minder, E. I. .

BRITISH JOURNAL OF DERMATOLOGY, 2015, 172 (06) :1601-1612

[3]

CIPRIANO M, KEEPING TRACK SCENES

[4] Health Preference Research: An Overview [J].

Craig, Benjamin M. ;

Lancsar, Emily ;

Muehlbacher, Axel C. ;

Brown, Derek S. ;

Ostermann, Jan .

PATIENT-PATIENT CENTERED OUTCOMES RESEARCH, 2017, 10 (04) :507-510

[5] Pitfalls and proposed solutions for patient communication about erythropoietic protoporphyria: A survey of parents and adult patients [J].

Dickey, Amy .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (05) :1204-1207

[6] Fifty years after thalidomide; what role for drug regulators? [J].

Eichler, Hans-Georg ;

Abadie, Eric ;

Baker, Mary ;

Rasi, Guido .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 74 (05) :731-733

[7]

*EMA, APPL NEW HUM MED EV

[8]

*EMA, PAT DISC BEN RISK EV

[9]

*EMA, OUTC REP PIL INV PAT

[10]

*EMA, EUR MED AG INT PAT C

← 1 2 3 4 →